Authored by Clarion, now part of Lumanity
Cancer care and outcomes suffer from wide disparities—by race, geography, socioeconomic status, gender, and other factors. At the 3rd Annual Emerging Frontiers in Oncology Summit, Clarion Managing Director, Dennis Chang, joined a group of industry leaders to discuss the issue and potential solutions. Dennis’ talk titled “From ‘Precision Medicine’ To ‘Inclusion Medicine’”, focused on how the development and delivery of cancer therapies would benefit from greater diversity, equity, and inclusion. We share the key points below:
- There are gaps in implementation of existing therapies and known best practices. For example, lower income countries continue to have devastatingly high rates of cervical cancer incidence and mortality—more than an order of magnitude higher than high-income countries—even though effective screening tests and treatments exist
- There are also gaps in new product development. For example, of the top 10 tumor types by number of products in clinical trials, 9 have the highest incidence rates in North America and Europe. Tumor types most common in Asia and Africa have more limited pipelines
- In order for all cancer patients to receive the best care, we need innovative solutions across both fronts: new models for collaborative implementation as well as new approaches to product development
Click here for the full presentation slides.
